Skip to content

Study · Randomized controlled trial · n = 35 · 2017

13 results

Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.

Tonneijck L, Muskiet MHA, Smits MM, Hoekstra T, Kramer MHH, Danser AHJ, Diamant M, Joles JA, van Raalte DH

Diabetes, obesity & metabolism25 Jul 2017Cited by 55 (Europe PMC)

PMID28449402 (opens in a new tab)DOI10.1111/dom.12985 (opens in a new tab)PepBankPUB-28449402
Source linkPubMedAsk about this study
Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In overweight patients with type 2 diabetes on insulin glargine, lixisenatide did not affect postprandial GFR versus insulin glulisine (difference +0.1 mL/min/1.73 m², 95% CI -9 to 9).

    In plain wordsIn patients with diabetes, lixisenatide did not affect kidney filtration after a meal compared with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    No significant changePostprandial GFR
    Study

    n = 35

    Comparator
    Insulin glulisine
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Measurements

    GFR difference
    0.1 mL/min/1.73 m²
    95% CI -9 to 9

    Source sentences

    Summary
    Compared with iGlu, lixisenatide did not affect GFR [+0.1 mL/min/1.73 m2 (95% CI -9 to 9)], ERPF [-17 mL/min/1.73 m2 (-61 to 26)],
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In overweight patients with type 2 diabetes on insulin glargine, lixisenatide did not affect postprandial effective renal plasma flow versus insulin glulisine (difference -17 mL/min/1.73 m², interval -61 to 26).

    In plain wordsIn patients with diabetes, lixisenatide did not affect kidney plasma flow after a meal compared with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    No significant changePostprandial effective renal plasma flow
    Study

    n = 35

    Comparator
    Insulin glulisine
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Measurements

    ERPF difference
    −17 mL/min/1.73 m²
    95% CI -61 to 26

    Source sentences

    Summary
    Compared with iGlu, lixisenatide did not affect GFR [+0.1 mL/min/1.73 m2 (95% CI -9 to 9)], ERPF [-17 mL/min/1.73 m2 (-61 to 26)],
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In overweight patients with type 2 diabetes, lixisenatide did not affect other renal haemodynamics versus insulin glulisine.

    In plain wordsIn patients with diabetes, lixisenatide did not affect other kidney haemodynamics compared with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    No significant changeOther renal haemodynamics
    Study

    n = 35

    Comparator
    Insulin glulisine
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    other (intra-)renal haemodynamics or renal damage markers,
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In overweight patients with type 2 diabetes, lixisenatide increased fractional sodium excretion by +0.25% versus insulin glulisine (95% CI 0.09-0.41).

    In plain wordsIn patients with diabetes, lixisenatide increased urinary sodium excretion compared with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseFractional sodium excretion
    Study

    n = 35

    Comparator
    Insulin glulisine
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Measurements

    Fractional sodium excretion difference
    0.25%
    95% CI 0.09-0.41

    Source sentences

    Summary
    but increased fractional sodium excretion [+0.25% (0.09-0.41)] and urinary pH [+0.7 (0.3-1.2)].
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In overweight patients with type 2 diabetes, lixisenatide increased urinary pH by +0.7 versus insulin glulisine (95% CI 0.3-1.2).

    In plain wordsIn patients with diabetes, lixisenatide increased urinary pH compared with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    IncreaseUrinary pH
    Study

    n = 35

    Comparator
    Insulin glulisine
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Measurements

    Urinary pH difference
    0.7 pH units
    95% CI 0.3-1.2

    Source sentences

    Summary
    but increased fractional sodium excretion [+0.25% (0.09-0.41)] and urinary pH [+0.7 (0.3-1.2)].
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, HbA1c fell similarly with lixisenatide and insulin glulisine, by 0.8% ± 0.1% and 0.6% ± 0.1%, respectively.

    In plain wordsIn patients with diabetes, lixisenatide and insulin glulisine reduced HbA1c similarly.

    Peptide
    Lixisenatide
    Outcome
    Direction not reportedHbA1c reduction
    Study

    n = 35

    Comparator
    Insulin glulisine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Measurements

    HbA1c reduction
    0.8%
    lixisenatide, reported as 0.8% ± 0.1%
    HbA1c reduction
    0.6%
    insulin glulisine, reported as 0.6% ± 0.1%

    Source sentences

    Summary
    Lixisenatide and iGlu reduced HbA1c similarly, by 0.8% ± 0.1% and 0.6% ± 0.1%, respectively, while postprandial glucose was lower with lixisenatide (P = .002).
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, postprandial glucose was lower with lixisenatide than insulin glulisine (P = .002).

    In plain wordsIn patients with diabetes, postmeal glucose was lower with lixisenatide than insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    DecreasePostprandial glucose
    Study

    n = 35

    Comparator
    Insulin glulisine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Measurements

    P value
    0.002
    postprandial glucose, lixisenatide vs insulin glulisine

    Source sentences

    Summary
    Lixisenatide and iGlu reduced HbA1c similarly, by 0.8% ± 0.1% and 0.6% ± 0.1%, respectively, while postprandial glucose was lower with lixisenatide (P = .002).
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide reduced body weight versus insulin glulisine (difference -1.4 kg, interval -2.5 to -0.2).

    In plain wordsIn patients with diabetes, lixisenatide reduced body weight compared with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    DecreaseBody weight
    Study

    n = 35

    Comparator
    Insulin glulisine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Measurements

    Body weight difference
    −1.4 kg
    lixisenatide minus insulin glulisine, interval -2.5 to -0.2

    Source sentences

    Summary
    Compared with iGlu, lixisenatide reduced bodyweight [-1.4 kg (-2.5 to -0.2)] and increased postprandial mean arterial pressure [+9 mm Hg (4-14)].
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with type 2 diabetes, lixisenatide increased postprandial mean arterial pressure versus insulin glulisine by +9 mm Hg (95% CI 4-14).

    In plain wordsIn patients with diabetes, lixisenatide increased postmeal mean arterial pressure compared with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    IncreasePostprandial mean arterial pressure
    Study

    n = 35

    Comparator
    Insulin glulisine
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Measurements

    Postprandial mean arterial pressure difference
    9 mm Hg
    lixisenatide minus insulin glulisine, interval 4-14

    Source sentences

    Summary
    Compared with iGlu, lixisenatide reduced bodyweight [-1.4 kg (-2.5 to -0.2)] and increased postprandial mean arterial pressure [+9 mm Hg (4-14)].
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In overweight patients with type 2 diabetes, lixisenatide did not affect renal damage markers versus insulin glulisine.

    In plain wordsIn patients with diabetes, lixisenatide did not affect kidney damage markers compared with insulin glulisine.

    Peptide
    Lixisenatide
    Outcome
    No significant changeRenal damage markers
    Study

    n = 35

    Comparator
    Insulin glulisine
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared with iGlu, lixisenatide did not affect GFR [+0.1 mL/min/1.73 m2 (95% CI -9 to 9)], ERPF [-17 mL/min/1.73 m2 (-61 to 26)], other (intra-)renal haemodynamics or renal damage markers,
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  11. 11HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes treated with lixisenatide, plasma renin was reported as unchanged; the abstract does not name the comparison.

    In plain wordsIn patients with diabetes, plasma renin was reported as unchanged with lixisenatide.

    Peptide
    Lixisenatide
    Outcome
    No significant changePlasma renin
    Study

    n = 35

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Plasma renin, angiotensin-II and aldosterone were unchanged.
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  12. 12HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes treated with lixisenatide, angiotensin-II was reported as unchanged; the abstract does not name the comparison.

    In plain wordsIn patients with diabetes, angiotensin-II was reported as unchanged with lixisenatide.

    Peptide
    Lixisenatide
    Outcome
    No significant changeAngiotensin-II
    Study

    n = 35

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Plasma renin, angiotensin-II and aldosterone were unchanged.
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.
  13. 13HumanNon-randomized trialEfficacy outcome

    In patients with type 2 diabetes treated with lixisenatide, aldosterone was reported as unchanged; the abstract does not name the comparison.

    In plain wordsIn patients with diabetes, aldosterone was reported as unchanged with lixisenatide.

    Peptide
    Lixisenatide
    Outcome
    No significant changeAldosterone
    Study

    n = 35

    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    20 µg · 8 weeksAs given in this study (human).

    Source sentences

    Summary
    Plasma renin, angiotensin-II and aldosterone were unchanged.
    1 context sentence
    Title · context
    Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02276196

Effect of LIXIsenatide on the Renal System

Amsterdam UMC, location VUmcn = 40Sept 2014 to Apr 2016

Diabetic Kidney Disease · Diabetic Nephropathy · Diabetes Mellitus · Glucagon-Like Peptide 1

Trial pageClinicalTrials.govUpdated 29 Apr 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.